Breaking News Instant updates and real-time market news.

PCRX

Pacira

$37.40

0.55 (1.49%)

, HRTX

Heron Therapeutics

$37.85

0.35 (0.93%)

10:16
07/25/18
07/25
10:16
07/25/18
10:16

Leerink healthcare/pharma analysts to hold a dinner meeting

Analysts hold a Post-Operative Pain Investor Dinner Meeting, along with two Key Opinion Leaders, to discuss Pacira's Exparel and Heron's HTX-01, in New York on July 25 hosted by Leerink.

PCRX

Pacira

$37.40

0.55 (1.49%)

HRTX

Heron Therapeutics

$37.85

0.35 (0.93%)

  • 02

    Aug

PCRX Pacira
$37.40

0.55 (1.49%)

06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
06/21/18
BMOC
06/21/18
NO CHANGE
BMOC
Market Perform
Pacira's Exparel may face greater threat from Heron drug, says BMO Capital
BMO Capital analyst Gary Nachman said the newly released Phase 2b data for Heron Therapeutics' (HRTX) HTX-011 in post-surgical pain support a "very solid profile" for the drug, which he thinks will eventually likely be a "viable competitor" to Pacira's (PCRX) Exparel. Given the new data, a more cautious long-term outlook for Exparel may be warranted, contends Nachman, who keeps a Market Perform rating on Pacira shares. In late day trading, Heron shares are up 29% to $39.70, while Pacira has fallen 12% to $34.98.
07/02/18
MZHO
07/02/18
NO CHANGE
Target $31
MZHO
Neutral
Pacira tracking ahead of consensus estimates, says Mizuho
Mizuho analyst Irina Koffler says "strong" May Exparel data indicate Pacira Pharmaceuticals is tracking slightly above consensus estimates. A raise to 2018 guidance would not be surprising at this point, Koffler tells investors in a research note. She reiterates a Neutral rating on Pacira shares with a $31 price target.
07/10/18
HCWC
07/10/18
NO CHANGE
HCWC
Pacira Q2 sales beat biggest in four years, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says this morning's Q2 preannouncement marks the biggest Exparel sales beat in four years for Pacira Pharmaceuticals. Strong Exparel growth shows follow-through from Q1 and likely upside to guidance, Livnat tells investors in a research note. The analyst reiterates a Buy rating on Pacira with a $48 price target.
HRTX Heron Therapeutics
$37.85

0.35 (0.93%)

06/22/18
LEER
06/22/18
NO CHANGE
Target $46
LEER
Outperform
Heron Therapeutics price target raised to $46 from $36 at Leerink
Leerink analyst Ami Fadia raised her price target for Heron Therapeutics to $46 citing yesterday's "strong" Phase 2b data release for HTX-011 in post-operative pain. The analyst believes there is still additional value for HTX-011 beyond what is implied at current stock levels. Yesterday's positive data lends to an investor debate as to whether Heron could potentially get acquired, as HTX-011 is "now a clearly differentiated product with a de-risked regulatory pathway at a time when curbing opioid use is of high priority for patients, clinicians and governments alike," Fadia tells investors in a research note. The analyst, however, does not assume upside from a buyout at this time. She reiterates an Outperform rating on Heron Therapeutics.
06/22/18
NEED
06/22/18
NO CHANGE
Target $66
NEED
Buy
Heron Therapeutics price target raised to $66 from $42 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $66 after the company reported phase 2B results in the total knee arthroplasty and breast augmentation, as its HTX-011 data met the endpoints in both trials with superior pain relief. The analyst adds that Heron has now reported positive results from seven phase 2 trials across 5 different surgical models, while estimating the HTX-011 program to address surgical procedures in a target market of about 15M cases. Belanger keeps his Buy rating on Heron Therapeutics.
06/25/18
EVER
06/25/18
NO CHANGE
Target $80
EVER
Outperform
Heron Therapeutics remains a top midcap pick at Evercore ISI
Evercore ISI analyst Josh Schimmer met with Heron Therapeutics management and sees substantial opportunity for HTX-011 to transform the surgical landscape. The analyst said '011 is poised to enter the market in 1H 2019 and has blockbuster potential and said survey work suggests a strong adoption opportunity. Schimmer believes Heron is one of the most compelling names in the space and remains a top midcap pick with an Outperform rating and $80 price target.
07/19/18
CANT
07/19/18
NO CHANGE
Target $50
CANT
Overweight
Heron Therapeutics price target raised to $50 from $40 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target for Heron Therapeutics to $50 after spending a day on the road with CEO Barry Quart. The analyst cites multiple expansion for her target raise, which she thinks is supported by a likely faster than expected product launch for HTX-011 next year. She notes Heron is seeking a price for HTX-011 that can get extensive utilization and minimal restrictions. Further, she believes a takeover of the company is "possible if the price is right." Chen keeps an Overweight rating on Heron Therapeutics.

TODAY'S FREE FLY STORIES

RICK

RCI Hospitality

$16.80

0.08 (0.48%)

17:13
07/18/19
07/18
17:13
07/18/19
17:13
Hot Stocks
RCI Hospitality auditor BDO resigns, company files Nasdaq compliance plan »

RCI Hospitality announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$9.60

-0.06 (-0.62%)

17:03
07/18/19
07/18
17:03
07/18/19
17:03
Earnings
Bright Scholar reports Q3 EPS 16c, two estimates 21c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:03
07/18/19
07/18
17:03
07/18/19
17:03
Hot Stocks
Intuitive Surgical refines FY19 procedure growth view to 16%-17% from 15%-17% »

Still sees FY19 tax rate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

CUB

Cubic

$66.59

-0.37 (-0.55%)

17:01
07/18/19
07/18
17:01
07/18/19
17:01
Hot Stocks
Cubic receives extension on simulation services contract in Australia »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRO

ClearOne

$2.27

(0.00%)

16:52
07/18/19
07/18
16:52
07/18/19
16:52
Hot Stocks
Shure files patent infringement suit against ClearOne »

Shure announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

16:50
07/18/19
07/18
16:50
07/18/19
16:50
Hot Stocks
Intuitive Surgical says 74% of systems placed in Q2 were da Vinci XIs »

Says team has done a nice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

ETN

Eaton

$79.03

-0.36 (-0.45%)

16:49
07/18/19
07/18
16:49
07/18/19
16:49
Hot Stocks
Eaton acquires Innovative Switchgear Solutions »

Eaton announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

ZNGA

Zynga

$6.30

0.07 (1.12%)

16:47
07/18/19
07/18
16:47
07/18/19
16:47
Hot Stocks
Zynga to expand India market with larger space in 'central hub' Bengaluru »

Earlier on Thursday,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 13

    Nov

FNF

Fidelity National

$42.65

-0.045 (-0.11%)

16:43
07/18/19
07/18
16:43
07/18/19
16:43
Recommendations
Fidelity National analyst commentary at Keefe Bruyette »

Fidelity National price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 13

    Nov

AIG

AIG

$55.58

0.2 (0.36%)

16:43
07/18/19
07/18
16:43
07/18/19
16:43
Upgrade
AIG rating change at William Blair »

AIG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

GOGL

Golden Ocean

$6.63

0.08 (1.22%)

16:42
07/18/19
07/18
16:42
07/18/19
16:42
Syndicate
Breaking Syndicate news story on Golden Ocean »

Golden Ocean files $400M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$361.17

-8.28 (-2.24%)

16:38
07/18/19
07/18
16:38
07/18/19
16:38
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing up over 1% at $366…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

ORCC

Owl Rock

$15.40

(0.00%)

16:38
07/18/19
07/18
16:38
07/18/19
16:38
Initiation
Owl Rock initiated at Compass Point »

Owl Rock initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FFBC

First Financial Bancorp

$23.90

0.51 (2.18%)

16:37
07/18/19
07/18
16:37
07/18/19
16:37
Hot Stocks
First Financial Bancorp increases dividend 1c to 23c per share »

First Financial Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

KSANF

Kansai Paint

$0.00

(0.00%)

, PPG

PPG

$117.00

0.395 (0.34%)

16:37
07/18/19
07/18
16:37
07/18/19
16:37
Periodicals
Axalta Coating interests rivals PPG and Kansai Paint, Bloomberg reports »

Axalta Coating (AXTA) has…

KSANF

Kansai Paint

$0.00

(0.00%)

PPG

PPG

$117.00

0.395 (0.34%)

AKZOY

AkzoNobel

$0.00

(0.00%)

AXTA

Axalta Coating

$30.40

0.175 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Jul

  • 25

    Jul

  • 05

    Aug

GBCI

Glacier Bancorp

$38.75

0.12 (0.31%)

16:36
07/18/19
07/18
16:36
07/18/19
16:36
Earnings
Glacier Bancorp reports Q2 EPS 61c, consensus 59c »

Reports Q2 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Aug

AA

Alcoa

$23.42

0.27 (1.17%)

16:35
07/18/19
07/18
16:35
07/18/19
16:35
Downgrade
Jefferies downgrades Alcoa to Hold, cuts price target to $23 from $29 »

Jefferies analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

BA

Boeing

$361.17

-8.28 (-2.24%)

16:35
07/18/19
07/18
16:35
07/18/19
16:35
Hot Stocks
Boeing says will issue new FY19 guidance at future date »

Boeing states that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

SEM

Select Medical

$15.65

0.105 (0.68%)

16:33
07/18/19
07/18
16:33
07/18/19
16:33
Earnings
Select Medical sees Q2 ops revenue $1.36B-$1.362B, consensus $1.35B »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 14

    Aug

BA

Boeing

$361.17

-8.28 (-2.24%)

16:33
07/18/19
07/18
16:33
07/18/19
16:33
Hot Stocks
Boeing to record $4.9B or $8.74 per share Q2 charge on 737Max grounding »

Boeing will record an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CVBF

CVB Financial

$20.80

0.165 (0.80%)

16:33
07/18/19
07/18
16:33
07/18/19
16:33
Hot Stocks
CVB Financial announces CEO Chris Myers to retire effective March 15, 2020 »

CVB Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

BANF

BancFirst

$55.18

0.5 (0.91%)

16:32
07/18/19
07/18
16:32
07/18/19
16:32
Earnings
BancFirst reports Q2 EPS $1.02, consensus 93c »

The company's net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYL

Dragon Victory

$0.94

(0.00%)

16:32
07/18/19
07/18
16:32
07/18/19
16:32
Hot Stocks
Dragon Victory receives Nasdaq staff deficiency letter »

Dragon Victory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$361.17

-8.28 (-2.24%)

16:31
07/18/19
07/18
16:31
07/18/19
16:31
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing to record $4.9B or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

OPOF

Old Point Financial

$23.00

(0.00%)

16:31
07/18/19
07/18
16:31
07/18/19
16:31
Hot Stocks
Old Point Financial chairman Robert F. Shuford, Sr. announces retirement »

Robert F. Shuford, Sr.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.